Trials / Active Not Recruiting
Active Not RecruitingNCT05089734
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 603 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Sacituzumab Govitecan-hziy (SG) | Administered intravenously |
| DRUG | Docetaxel | Administered intravenously |
Timeline
- Start date
- 2021-11-17
- Primary completion
- 2023-11-29
- Completion
- 2026-01-01
- First posted
- 2021-10-22
- Last updated
- 2025-05-23
- Results posted
- 2025-01-14
Locations
227 sites across 20 countries: United States, Australia, Austria, Belgium, Brazil, Canada, France, Germany, Greece, Israel, Italy, Japan, Mexico, Netherlands, Poland, Portugal, Puerto Rico, Spain, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05089734. Inclusion in this directory is not an endorsement.